Drug Profile
MRX III
Alternative Names: NeoamiyuLatest Information Update: 26 Aug 2004
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Amino acids
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Nutrition disorders
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 30 Sep 1996 Launched for Nutritional disorders in Japan (IV)
- 27 Aug 1996 Preregistration for Nutritional disorders in Japan (IV)